We further validated PIK3C2A as a driver of EGFR inhibitor resistance by CellTiter‐Glo viability assays and investigated how the combination of the EGFR inhibitor with PIK3C2A knockout impacts HNSCC viability. Here, PIK3C2A is linked to head and neck squamous cell carcinoma.